INTRODUCTION
Primary sclerosing cholangitis (PSC) is a progressive fibro-inflammatory cholangiopathy stigmatised by a disproportionate impact on young patients [1, 2] .
Presently, liver transplantation is the only proven life-extending intervention, and PSC now accounts for 10 -15% of all liver transplant activity within Europe [3] [4] [5] . In parallel, the overall number of patients with chronic liver disease on an active liver transplant register is increasing globally [4] [5] [6] , without an appropriate rise in the donor pool [7] . A challenge more specific to PSC, is that patients may suffer complications inadequately represented by the model for end-stage liver disease (MELD) score; such as intractable pruritus, recurrent ascending cholangitis, and reduced overall quality of life [8] . Consequently, the number of PSC patients who die or are withdrawn from a transplant waiting list due to clinical deterioration is rising, and now approximates 20% [9] . This group of invariably young individuals may have their life saved in the event of timely donor availability. Donation after brain death (DBD) is the practice of choice in liver transplantation, although the increasing demand for organs has furthered interest in using grafts donated after circulatory death (DCD). Indeed, the advances in graft preservation, immunosuppression and operative techniques have significantly improved clinical outcomes following DCD grafting [10] . However, DCD livers are still used prudently [11] , given the risk of acute kidney injury (AKI) and ischaemic type biliary lesions (ITBL) [12] [13] [14] [15] [16] . The latter are defined radiologically, as biliary strictures and dilatations occurring in the absence of hepatic artery stenosis or thrombosis, portal thrombosis, chronic ductopenic rejection, and recurrent PSC [14, 17] ; and associated clinically with significant patient morbidity, a need for multiple biliary interventional procedures and repeated hospital admissions [12, 18] .
The precise pathogenic mechanisms leading to ITBL are unknown, but postulated to involve ischaemia reperfusion injury (IRI), microvessel thrombosis and impaired cholangiocyte regeneration [14] . In transplantation for PSC more specifically, we also observe a high incidence of post-transplant biliary strictures attributable to recurrent disease [19, 20] . Development of the latter has also been attributed to poor quality in donor organs [21, 22] , and a proposal that IRI itself can lead to a de novo autoimmune cascade and recurrence of PSC in the transplanted liver. Such hypothesis suggests existence of a common mechanistic pathway in the pathogenesis of biliary strictures post liver transplantation [21, 23] . Furthermore, cholangiographic features of ITBL and recurrent PSC cannot be easily distinguished, and often reported collectively as non-anastomotic stricturing disease [19] .
The University Hospitals Birmingham NHS Foundation Trust (UHB) contributes 25% of all liver transplant activity in the United Kingdom (UK); and in contrast to several other centres, our decline rate for offered DCD liver grafts was only ~20% by 2016 [5] . We select recipients for a DCD graft who are deemed 'low-risk,' for instance patients with MELD scores enough to warrant transplantation, but too low to reach priority on the waiting list. This contrasts to institutional policy elsewhere, wherein high MELD scoring patients are preferentially selected due to the survival benefit from early transplantation being greatest for this group [24] [25] [26] . However, our experience as well as that of certain others, is that patients having a low MELD score are more likely to achieve survival benefit with a DCD liver compared to prolonged transplant wait-list times; whereas those with a high-risk phenotype experience an 8 increased rate of graft failure and post-transplant complications [10, 27, 28] .
Furthermore, all DCD retrievals are derived from controlled donors (Maastricht III) [29] and we have shown that with appropriate recipient selection and maintaining low ischaemic times, DCD livers yield outcomes similar to DBD transplantation [10] .
Nevertheless, liver transplantation for PSC across many centres is restricted to the usage of DBD grafts [19] , due to apprehensions of post-transplant biliary complications. Given that the incidence of PSC is rising [30] , while the prevalence of an 'ideal' donation pool continues to decline, the usage of liver grafts arising from DCD donors seems unavoidable in clinical practice. Thus, the aim of this study was to determine the clinical impact of using liver grafts donated after circulatory death in patients specifically undergoing transplantation for PSC.
PATIENTS AND METHODS

Study population
We reviewed a prospectively collected, well-characterised database of all adult patients undergoing liver transplantation since the date of our first DCD transplant in a PSC patient (February 2006 ) and up until January 2016. The hospital transplant database is maintained prospectively and contains information on the donor, the recipient, the retrieval process, the peri-operative period, complications and followup, as detailed elsewhere [10] . In order to ensure robustness, accuracy and completeness of data for our PSC cohort, the transplant database was cross-referenced with an independently accrued registry of all patients having previously attended or under current follow-up of the Birmingham PSC clinic since September 1983. Only patients transplanted between 2006 and 2016 were selected for this study.
Clinical endpoints
The 'time-dependent' clinical endpoints for our study were as follows:
A) Graft loss and patient mortality (primary study endpoint). B) Primary vascular injury; specifically hepatic artery thrombosis (HAT) and hepatic artery stenosis (HAS) -evident on contrasted computed tomography (CT), magnetic resonance imaging (MRI) or dedicated angiography. C) Biliary stricturing disease; with sub-analysis specifically for non-anastomotic strictures -evident on cholangiography (either magnetic resonance or endoscopic retrograde cholangiopancreatography; MRCP or ERCP, respectively). When referring to non-anastomotic biliary strictures collectively, this pertains to lesions developing in the absence of ABO incompatibility, chronic rejection or hepatic artery compromise, i.e. focussing on ITBL and recurrent PSC.
The need and type of interventions required following development of vascular or biliary complications were classified as endoscopic/radiological, reconstructive surgery and need for re-transplantation. Post-operative complications were also documented according to the Clavien-Dindo grading system (IIIa and IIIb), and when a patient required multiple procedures the level of highest intervention was chosen for analysis [31] .
Patients were censored at the date of last follow-up if they did not meet the clinical endpoint in question. In addition, primary graft non-function, bile leaks or acute kidney injury (AKI) were assessed as peri-operative 'categorical' endpoints with a binary outcome measure. The latter was defined with reference to the 'Risk, Injury, Failure, Loss, End-stage kidney disease' (RIFLE) criteria [32] .
Statistical analysis
Data are presented using the median and interquartile range (IQR) for continuous variables. The non-parametric Mann-Whitney U-test was used to determine whether significant differences existed between groups. Differences in nominal data were compared by Fisher's exact test. A p value of <0.05 was deemed statistically significant.
Clinical outcomes' analysis was performed through Kaplan-Meier survivorship estimates, and significant differences between groups assessed by Log-rank testing.
The proportion of clinical events are presented as cumulative incidence (%) and as incidence rates (IR) per 100-patient-years with respective confidence intervals (95% CI). Additionally, Cox proportional hazards models were fit in order to assess the impact of individual covariates on the instantaneous rate of respective events (hazard ratios [HR] 6.60 -8.82 events per 100-patient-years).
Peri-operative course of PSC-DCD versus PSC-DBD liver transplant recipients
Within our PSC cohort, 35 patients received liver donation after circulatory death.
Characteristics were similar between DBD and DCD groups, although recipients of the latter were observed to have lower MELD scores, shorter warm ischaemic times (WIT / implantation time) and shorter donor cold ischaemic times (CIT) (Supplementary Table 1 ). The median donor functional warm ischaemic time for DCD livers was 20 minutes.
Comparing donor groups, there were no significant differences in the median duration of surgery, transfusion requirements, duration of intensive care unit (ICU) stay or duration of hospital stay in total. Post-operative bile leaks were more common in recipients of a DCD liver, who also trended an increased risk of renal injury. These differences were not, however, statistically significant, even after restricting the analysis to transplantation using non-split livers ( Table 1) . Table 2 
Transplantation in PSC is associated with a high incidence of vascular events
Incidence of post-transplantation biliary strictures is independent of donor type
In our PSC cohort, 31.5% of transplanted patients (n=45) developed recurrent biliary strictures, 6 of which were attributed to hepatic artery stenosis (DBD=3 vs. DCD=3, cases, the choice of duct-to-duct anastomosis was made when the recipient biliary tree was free from extra-hepatic disease, including 2 patients with significant bowel wall oedema, 1 individual with prior small bowel resection (due to Crohn's disease) and 2
with extensive intra-abdominal adhesions. No patient with duct-to-duct anastomosis developed post-transplant biliary malignancy.
The incidence of non-anastomotic biliary strictures overall (NAS), as well as eventfree survival at 6-and 12-months was not significantly different when stratified by donor type (Figure 1) . Although duct-to-duct anastomoses were more common in our DCD group (Table 1) 
Graft loss and patient mortality rates are similar for DCD versus DBD recipients
With regard to our primary endpoint, we observed no significant differences in graft or patient survival times between donor types, even after excluding recipients of split livers ( Table 2) .
Outcomes for DCD transplantation in PSC are akin to non-PSC DCD recipients
Next, we compared the post-transplant outcomes in our PSC cohort versus that observed for other aetiologies (Supplementary Table 5 and Supplementary Table   6 ). The overall rate of graft loss was greater following liver transplantation for PSC (Table 3 and Supplementary Figure 4) , albeit with no significant differences in patient mortality, or graft loss/mortality as a combined endpoint.
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The proportion of patients developing HAT was greater in our PSC vs. Figure 5A) , indicative of the burden of recurrence. However, the incidence rate of ITBL, specifically, was not significantly different between groups receiving a DCD liver (Supplementary Figure 5A) .
DISCUSSION
Herein, we describe the clinical course following liver transplantation across a contemporary cohort of PSC patients stratified by donor type; specifically DCD versus DBD graft recipients. In so doing, we found no significant differences in transfusion requirement, need for organ support post-transplant, or length of hospital stay between groups. Whilst the incidence of ITBL was heightened in DCD recipients, the risk of AKI, HAT, or biliary strictures overall, was not significantly increased when compared with the DBD group over time. Perhaps most apparent, was the finding that DCD versus DBD transplantation did not adversely affect recipient or graft survival in PSC; and whilst the rate of graft loss was significantly greater compared to non-PSC patients, this was not confined to a particular donor type.
As an aetiology of chronic liver disease, the burden of PSC on younger patients is substantial, with a median age of transplantation below 50 years. Thus, there is a need to maximise the number of 'life-years' gained after transplantation, and clinicians who manage PSC strive to provide patients with the best graft possible. Unfortunately the divide between an optimum donation pool and the number of patients who require liver transplantation is increasing. The transplant community must therefore capitalise on the reach of DCD grafts in response to the rising burden not just of PSC [30] , but also of chronic liver disease in general [33] . In the UK, the number of patients on the active liver transplant register has more than doubled in the last ten years, and in response there has been an exponential rise in the usage of DCD grafts [5, 6] .
Conversely, the United Network for Organ Sharing (UNOS) database from North
America indicates that donation after circulatory death increases the odds of liver non-use by four-fold [11] . The increasing reluctance to use DCD livers largely reflects the perception that post-transplant outcomes are worse, in particular the development of ITBL [12] [13] [14] 24, 34, 35] .
Such apprehensions may be heightened particularly in patients with PSC, who harbour an additive risk of post-transplant biliary strictures related to recurrent disease [19] [20] [21] . The morphological features of recurrent PSC are often difficult to distinguish from biliary strictures due to ITBL, and presently there is no single diagnostic tool permitting accurate differentiation with absolute certainty. In addition to the impact of marginal donor organ quality [14] , ITBL develops most commonly in the first 6 -12 months following transplantation [36] . This contrasts with reports of PSC recurrence, which tends to manifest after the first year [37] . Histopathology may also complement clinical and radiological suspicion; for instance, widespread ulceration and necrosis of the large bile duct branches as well as arteriolonecrosis are described for ITBL, but such features are infrequent in PSC [38, 39] .
With these caveats in mind, we observed no significant difference in incidence of NAS overall between PSC DBD vs. PSC DCD patients across multiple time points.
However, strictures that were felt more in keeping with ITBL developed exclusively in the first 12 months and concordant with receiving a DCD liver. In any event the number requiring interventional procedures -a major determinant of quality of lifewas similar between donor groups, even in a sub-analysis of intervention type. This has implications for the appropriate counselling of patients who are at risk of developing post-transplant stricturing disease, although longer-term, multi-centre studies are required to validate our experience.
The traditional method of biliary anastomosis in liver transplantation for PSC is
Roux-en-Y choledochojejunostomy [40] ; and whilst some investigators report success with choledochoduodenostomy, the approach is not universally favoured given concerns over duodenal leaks and overall biliary complications [41, 42] . Additionally, 21 patients in our cohort underwent duct-to-duct biliary reconstruction and in all cases this was when the recipient common bile duct was free of visible disease. Historically, duct-to-duct anastomosis was not opted for in PSC transplantation given the perceived risk of recurrent biliary strictures [40] , and theoretically, malignant degeneration.
However, more contemporary data including that from meta-analyses indicate there is no increased risk when compared to Roux-en-Y choledochojejunostomy [43] [44] [45] [46] [47] ;
findings validated convincingly in our study. Duct-to-duct anastomosis more effectively restores the natural anatomy and function of the biliary tree, maintains normal sphincter function (putatively reducing the incidence of cholangitis episodes), and facilitates easier accessibility to the bile ducts by ERCP post-transplant. This is highly relevant for PSC patients, given the incidence with which NAS occur. By contrast, there may arise circumstances wherein Roux-en-Y anastomosis is less favourable, for instance in patients with previous surgery resulting in a shortened small bowel, extensive intra-abdominal adhesions, small bowel oedema due to portal hypertension, or if there has been prolonged portal vein clamping during the transplant procedure.
Pathophysiological understanding of non-anastomotic biliary stricturing is incomplete, although the risks for developing ITBL and recurrent PSC are probably linked to donor graft quality and factors inherent to the recipient, respectively.
However, overlapping mechanistic insults have been proposed, including putative micro-angiopathic aetiology and a 'toxic bile' hypothesis [14, 23, [48] [49] [50] , illustrating how a multitude of biologic pathways result in a common phenotypic manifestation.
In any event, no evidence-based therapy has been consistently proven to improve graft survival for either entity, and re-transplantation may be indicated for both.
Whilst it can be argued that management strategies should differ, our threshold for intervention (including the need for re-transplantation) remains driven by the extent/distribution of biliary stricturing, severity of graft dysfunction, and/or the burden of recurrent biliary sepsis; not whether strictures are formally labelled as ITBL or PSC recurrence.
With regard to clinical outcome, the literature presents a conflicting picture, with multi-centre registries indicating a relatively high graft failure rate with DCD livers [34, 35] ; whereas smaller, yet 'high-volume' single-centre studies indicate similar graft and patient survival following DBD transplantation [10, [51] [52] [53] . Furthermore, meta-analyses of clinical outcomes following DCD liver transplantation highlight a significant yet unexplained difference in effect size between individual contributing units [13, 54] . This may explain our discrepant findings compared with the UNOS report, which demonstrated a higher risk of graft loss following DCD transplantation in PSC despite maintaining similar donor functional warm ischaemic times (FWIT) [22] . Furthermore, DCD retrievals in the UK take place almost exclusively with the use of 'controlled' retrievals (according to Maastricht criteria), and in our centre provided to patients with low MELD scores. This contrasts with certain other European countries and the United States, where both controlled and uncontrolled DCD retrievals may be utilised [55] .
Notably, a greater incidence of graft loss was observed in PSC patients overall, despite this group having more favourable donor and recipient characteristics than their non-PSC counterparts; including younger donor and recipient age, lower donor and recipient body mass index (BMI), and shorter WIT and CIT. These findings suggest a more general predisposition to the development of post-transplant vascular and biliary injury. However, the incidence rate of HAT with DCD livers was not greater for PSC patients, rather increased specifically in the cohort with a history of pre-existing IBD. The latter harbours a well recognised association with PSC, and also with increased platelet activation and an increased risk of thromboembolism [56] .
Our study is not without limitation. Despite being the largest single-centre experience utilising DCD liver transplantation in PSC patients, external independent and prospective validation is of critical importance. Additionally, the lack of protocol cholangiographic / angiographic surveillance post-transplantation is caveat across most studies determining outcomes following liver transplantation, including those from our own centre. In this regard, it is conceivable that the sub-clinical incidence of vascular events and biliary strictures was higher than actually reported. Finally, it must be recognised that DCD liver transplantation is an evolving practice, and longerterm patient and graft survival impact have yet to be determined. • Operating time, days requiring critical care support, total ventilator days, incidence of acute kidney injury, need for renal replacement therapy (RRT) or total days requiring RRT were no different between DCD recipients vs. those receiving a liver donated after brain death (DBD).
• DCD vs. DBD transplantation is not associated with increased risk of hepatic artery thrombosis or non-anastomotic biliary strictures (NAS) overall; however results in an increased incidence of ischaemic-type biliary lesions (ITBL) in the first year.
• The risk of hepatic artery thrombosis is greatest in PSC patients with inflammatory bowel disease.
• Patient and graft survival is not significantly different for transplanted PSC patients receiving a DCD vs. DBD liver.
